Navigation Links
Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
Date:11/5/2007

tudy, more than 3,000 patients were tested for Haptoglobin phenotype, and 984 of these who had the Hp2-2 phenotype were randomized to receive either natural source Vitamin E (400 IU daily) or placebo. Primary endpoints of the study were non-fatal myocardial infarction (MI--heart attack), stroke and cardiovascular death. Results demonstrated a greater than 50% decrease in cardiovascular events in patients receiving Vitamin E (1.0 percent compared to 3.8 percent, p=0.004), leading to early termination of the study. Investigators determined this result to be predominantly due to a significant decrease in non-fatal myocardial infarction in the Vitamin E group.

"Our research group has postulated that the profoundly increased risk of, MI, stroke and cardiovascular death observed in DM patients with Hp2-2, established in many observational studies of more than 20,000 patients in recent years, may be a consequence of a defect in the antioxidant protection of Hp2-2," added Dr. Levy. "As a member of my group, Dr. Rabea Asleh, reported earlier today, this defect may interfere with reverse cholesterol transport. This in turn may promote a more inflamed and labile atherosclerotic plaque. It is gratifying to have had this opportunity to collaborate with Clalit Health Services, the largest health plan in Israel, in a large prospective clinical trial that provides strong support for the claim that Vitamin E can be targeted to DM patients with Hp2-2 and provide a significant clinical benefit."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metaboliz
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Braeburn Pharmaceuticals announced today ... focus beyond addiction and pain to include ... has acquired an implantable, six-month formulation of ... treatment of schizophrenia from Endo Pharmaceuticals. With ... to other potential applications of the implant ...
(Date:5/1/2015)... 2015 Semler Scientific, Inc. (Nasdaq: SMLR ... manufactures and markets products that assist healthcare providers in ... results for the first quarter ended March 31, 2015. ... Semler reported continued progress with year over year growth ... of 14%," said Doug Murphy-Chutorian , M.D., chief ...
(Date:4/30/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the fiscal year ended December ... in Canadian dollars unless otherwise stated. ... the right strategic partners and additional capitalization in ...
Breaking Medicine Technology:Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6
... the Millions Still Suffering from Chronic,Hepatitis B and C, ... for Disease,Control and Prevention (CDC) has reported that significant ... the United States,in the last 10 years, reflecting the ... Liver Foundation wants to,highlight these positive results, but remind ...
... tolerability profile Reduction of,testosterone concentration was maintained ... 2b trial, QUEBEC CITY, March 22, 2007 ... Japanese partner Shionogi & Co.,Ltd. today announced ... with,cetrorelix in benign prostatic hyperplasia (BPH) initiated ...
Cached Medicine Technology:The American Liver Foundation Urges Cautious Optimism about CDC,Report on Declining Acute Hepatitis Infection Rates 2The American Liver Foundation Urges Cautious Optimism about CDC,Report on Declining Acute Hepatitis Infection Rates 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 NuevaCare ... MnemeTherapy® at two upcoming area seminars. The first event ... PSA Annual Regional Stroke Conference to be held at ... offered on Wednesday, May 13 during the Dementia Conference ... , “These seminars offer an excellent opportunity to ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... at the , May 5 - 7, 2015 Minnesota ... at the conference include its bestselling TaskMate sit stand ... the 6100 TaskMate Executive. Features of the 6100 TaskMate ... tray, extended platform work surface and supply holders. Weighing ...
(Date:5/2/2015)... May 02, 2015 Vancouver fencing company, QS ... provide valuable advice to prospective clients related to their questions ... to install railings around their decks and patios. While that ... that pop up once the person rolls up their sleeve ... installing a railing in finding a gate that matches it. ...
(Date:5/2/2015)... New York, NY (PRWEB) May 02, 2015 ... – when a deadly natural disaster strikes anywhere on ... ways to leverage human sympathy and compassion for their ... US-CERT (United States Computer Emergency Readiness Team) issued ... warning users “of potential email scams citing the earthquake ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 On Tuesday ... City Hospital (ELCH) gathered to celebrate improvements in patient ... Valley Health Partners (RVHP), had zero acquired ventilator associated ... catheter associated infections. ELCH was also recently named a ... management team at ELCH credited the teamwork of staff ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Sept. 4 Symmetry Medical Inc.,(NYSE: SMA ... global orthopedic,device industry and other medical markets, announced ... of Specialty Surgical,Instruments (SSI) and Ultra Containers of ... and sterilization containers. About Symmetry Medical Inc. ...
... two drugs shows promise in treating a rare and therapy-resistant ... to other organs, according to a new study led by ... -- decitabine, which can turn on certain genes in cancer ... work together to cause cancer cell death. , Metastatic uveal ...
... that still kills 70,000 every year in developing countries worldwide ... nearly is always fatal when it reaches the brain. ... at Jefferson have shown how a type of bat rabies ... virus reaches the brain, when it is most lethal. They ...
... Novel treatment promotes blood vessel growth in heart muscle, ... A trial testing a genetically engineered treatment in women ... bedevil the millions of Americans with heart disease, ... and Drug Administration. , The study will enroll about ...
... Sept. 4 Martek,s life,sDHA(TM),from microalgae is ... in male,hypertriglyceridemic patients, according to a study ... Journal of Clinical Nutrition. In this study,DHA ... acid), the other omega 3 commonly found ...
... Sept. 4 In a recent New York,Times article ... turn far too quickly to drugs to solve their ... are reasonable measures people can take,first to control a ... or together, can help to lower LDLs." The Soyfoods ...
Cached Medicine News:Health News:Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments 2Health News:Promising drug combination may help those with ocular melanoma that has spread 2Health News:Jefferson immunology researchers halt lethal rabies infection in brain 2Health News:Jefferson immunology researchers halt lethal rabies infection in brain 3Health News:Trial to Test Gene Therapy for Angina in Women 2Health News:Trial to Test Gene Therapy for Angina in Women 3Health News:Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels 2Health News:Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels 3Health News:September: Time to Try Cholesterol-Free Soyfoods 2
Leica M500 MS3 robotic stand for neuro, spine surgery and ENT. Motorized XY-movement for precise positioning of the optical axis in eight directions, inclination and tilt....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
Advanced operating microscope with zoom and variable focus up to 500 mm....
... surgeons with brighter, crisper, magnified views of ... many minimally invasive spine procedures. It is ... of contact. The first graphical touchscreen to ... intuitive user guidance similar to that known ...
Medicine Products: